[
  {
    "ts": null,
    "headline": "Consumer sentiment, Regeneron meeting, Apple WWDC: What to Watch",
    "summary": "Market Domination Overtime hosts Julie Hyman and Josh Lipton preview the top market stories and headlines Wall Street will be paying attention to tomorrow, Friday, June 13, including June's preliminary consumer sentiment reading, Regeneron Pharmaceuticals' (REGN) annual shareholder meeting, and the closing day of Apple's (AAPL) 2025 Worldwide Developers Conference (WWDC). To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.",
    "url": "https://finnhub.io/api/news?id=8b87e4a761c6ca2c22de35ca37142d5ac38f9ff0e00370640a3bf9272141f364",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749769200,
      "headline": "Consumer sentiment, Regeneron meeting, Apple WWDC: What to Watch",
      "id": 135224419,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Market Domination Overtime hosts Julie Hyman and Josh Lipton preview the top market stories and headlines Wall Street will be paying attention to tomorrow, Friday, June 13, including June's preliminary consumer sentiment reading, Regeneron Pharmaceuticals' (REGN) annual shareholder meeting, and the closing day of Apple's (AAPL) 2025 Worldwide Developers Conference (WWDC). To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.",
      "url": "https://finnhub.io/api/news?id=8b87e4a761c6ca2c22de35ca37142d5ac38f9ff0e00370640a3bf9272141f364"
    }
  },
  {
    "ts": null,
    "headline": "Is This Stock a Buy After Acquiring a Potential Zepbound Competitor?",
    "summary": "Regeneron acquired a promising weight management asset that could become lucrative.  Shares of Regeneron (NASDAQ: REGN) have declined this year due to issues with one of its former growth drivers, Eylea, a medicine that treats wet age-related macular degeneration.  Is Regeneron stock a buy now?",
    "url": "https://finnhub.io/api/news?id=6bcfddc9c39176012bbd487026ff7c81f11e28c8c7564aa6bb51c80ab171d400",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749740700,
      "headline": "Is This Stock a Buy After Acquiring a Potential Zepbound Competitor?",
      "id": 135220836,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron acquired a promising weight management asset that could become lucrative.  Shares of Regeneron (NASDAQ: REGN) have declined this year due to issues with one of its former growth drivers, Eylea, a medicine that treats wet age-related macular degeneration.  Is Regeneron stock a buy now?",
      "url": "https://finnhub.io/api/news?id=6bcfddc9c39176012bbd487026ff7c81f11e28c8c7564aa6bb51c80ab171d400"
    }
  },
  {
    "ts": null,
    "headline": "JPMorgan Calls the Selloff Excessive, Trims Regeneron Pharmaceuticals, Inc. (REGN) Price Target",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) after reducing its price objective from $950 to $800. Following poor IL-33 data in late May, the company believes that the recent selloff in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares […]",
    "url": "https://finnhub.io/api/news?id=2ae1ec6dcfe89613c904707a915724e2fb5299666373452413a33e195c2408d6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749686495,
      "headline": "JPMorgan Calls the Selloff Excessive, Trims Regeneron Pharmaceuticals, Inc. (REGN) Price Target",
      "id": 135205765,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) after reducing its price objective from $950 to $800. Following poor IL-33 data in late May, the company believes that the recent selloff in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares […]",
      "url": "https://finnhub.io/api/news?id=2ae1ec6dcfe89613c904707a915724e2fb5299666373452413a33e195c2408d6"
    }
  }
]